RAPT Therapeutics

RAPT Therapeutics is a mission-driven biotech focused on developing novel therapeutics for inflammatory and immunologic diseases by targeting critical immune pathways like IgE and CCR4. Its primary achievement is the advancement of its lead asset, ozureprubart, a long-acting anti-IgE antibody with best-in-class potential, into Phase 2 trials for food allergy and chronic spontaneous urticaria. The company's strategy leverages a proprietary immunology platform to develop both biologics and small molecules, culminating in a significant strategic validation through its acquisition by global pharmaceutical leader GSK in January 2026. This exit provides substantial resources to accelerate the development of its pipeline.

A proprietary immunology-focused drug discovery engine that identifies and modulates key immune drivers (e.g., IgE, CCR4) to develop both long-acting biologics and oral small molecule therapies.

Ozureprubart competes directly with omalizumab (Xolair) and Roche's ligelizumab in the anti-IgE space, differentiating on dosing frequency. The CCR4 program enters a crowded atopic dermatitis market dominated by dupilumab and JAK inhibitors, requiring strong efficacy data to gain traction.